HIV Scientific Papers
Long-term efficacy, safety, and durability of ibalizumab-based regimens in subgroup of TMB-202 participants.
2020
Towner W, DeJesus E, Schrader S, et al.
Poster #1027 presented at: IDWeek; October 21-25, 2020; virtual.
Disease severity impact on long-term virologic response to ibalizumab in expanded access protocol (TMB-311) [abstract].
2020
Open Forum Infect Dis.
Kumar P, Leider J, Slim J, et al.
7(suppl 1):S532. Proceedings of IDWeek, 2020.
Disease severity impact on long-term virologic response to ibalizumab in expanded access protocol (TMB-311).
2020
Kumar P, Leider J, Slim J, et al.
Poster #1008 presented at: IDWeek; October 21-25, 2020; virtual.
Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection [abstract].
2020
Value in Health.
La EM, Talbird SE, Brogan AJ, Davis AE.
23:S174. Proceedings of the Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2020.
Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection.
2020
La EM, Talbird SE, Brogan AJ, Davis AE.
Poster #PIN31 presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 18-20 2020; virtual.